NBIX director exercises 3,318 RSUs
NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares.
Rhea-AI Filing Summary
NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares. On May 21, 2026, he converted 3,318 Restricted Stock Units into 3,318 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related vesting event rather than a market purchase or sale.
After this transaction, Rastetter’s direct holdings increased to 43,678 common shares, which are held by the Rastetter Family Trust, where he has voting and investment power. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, and no remaining derivative position is reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,318 shares exercised/converted
Exercise
2 txns
Insider
RASTETTER WILLIAM H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 3,318 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,318 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 0 contracts (Direct);
Common Stock — 43,678 shares (Direct)
Footnotes (3)
- F1. 43,678 of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power.
- F2. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
- F3. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.
Key Figures
RSUs exercised: 3,318 units
Shares received: 3,318 shares
Post-transaction holdings: 43,678 shares
+2 more
5 metrics
RSUs exercised
3,318 units
Restricted Stock Units converted to common stock on May 21, 2026
Shares received
3,318 shares
Common stock issued upon RSU conversion
Post-transaction holdings
43,678 shares
Common stock beneficially held after May 21, 2026 transaction
RSU grant date
May 21, 2025
Grant date of RSU award that is now fully vested
Exercise price
$0.00 per share
Stated price for RSU-to-common conversion
Key Terms
Restricted Stock Unit, derivative security, voting and investment power
3 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
voting and investment power financial
"of which the Reporting Person has voting and investment power."
FAQ
What insider transaction did William H. Rastetter report for NBIX?
William H. Rastetter reported exercising 3,318 Restricted Stock Units into 3,318 shares of Neurocrine Biosciences common stock. The transaction occurred on May 21, 2026, as a derivative exercise rather than an open-market buy or sell.
What happened to the 3,318 Restricted Stock Units reported in the NBIX Form 4?
The 3,318 Restricted Stock Units were converted into 3,318 shares of Neurocrine Biosciences common stock. Each RSU entitled the holder to receive one common share upon vesting, and the award referenced in the filing is fully vested.
Was the Neurocrine (NBIX) insider transaction a market purchase or sale?
The transaction was not a market purchase or sale; it was an exercise of a derivative security. Restricted Stock Units were converted into common shares at a stated price of $0.00 per share, reflecting equity compensation vesting rather than trading in the open market.
When was the Restricted Stock Unit award in the NBIX Form 4 originally granted?
The Restricted Stock Unit award referenced in the Form 4 was granted on May 21, 2025. By the time of the May 21, 2026 transaction, the award was fully vested, enabling conversion of all 3,318 RSUs into common shares.
Are there any remaining derivative securities for William H. Rastetter in this NBIX filing?
The filing does not show any remaining derivative securities for William H. Rastetter. The 3,318 Restricted Stock Units reported were fully converted into common shares, and the derivative summary in the data is empty after this exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
